2.50
Hdl Handle:
http://hdl.handle.net/10755/157256
Type:
Presentation
Title:
Once-Weekly vs. Daily Statin Dosing: Evidence-Based Practice in Action
Abstract:
Once-Weekly vs. Daily Statin Dosing: Evidence-Based Practice in Action
Conference Sponsor:Western Institute of Nursing
Conference Year:2009
Author:Reavy, Kathy, PhD, RN
P.I. Institution Name:Boise State University, Nursing
Title:Associate Professor
Contact Address:1910 University Dr., Boise, ID, 83725-1840, USA
Contact Telephone:208-426-1598
Co-Authors:Mary Hereford, Associate Professor; Sara O'Connor, Associate Professor; Mary Randall, BSN, RN
Purpose: The purpose for this project is to validate that prescribing once-weekly rosuvastatin is a safe and effective alternative to daily statin therapy in patients who have prior intolerance and non-compliance issues. Background: A recurrent problem was collaboratively identified by a physician and registered nurse team in an out-patient cardiology clinic.  Although most patients do relatively well with minimal side effects on once daily statin dosing, increasing numbers of patients were experiencing difficulty in tolerating daily statin therapy.  The most common complaint was myalgia.  These side effects contributed to patient non-compliance with the prescribed medication.   Identification of this problem led to an evidence-based practice project to find a solution. Evidence-Based Practice Process: (1) A review of the literature found only one publication related to daily dosing of statin medications.  A research study by Backes, Moriarty, Ruisinger, and Gibson (2007) published in The American Journal of Cardiology concluded that once weekly dosing of rosuvastatin in place of daily dosing achieved a mean reduction in LDL cholesterol of 29%, with percentages ranging from 6% to 62%. The sample size in that study, however, was only 8 patients.  (2) Based on patient need, review of the literature, and review of pharmacologic documents, the decision was made to trial identified patients on once-weekly dosing of rosuvastatin.  (3)  Validation of dosing efficacy, patient safety, and patient compliance were evaluated with chart reviews.  A minimum of 100 patient charts will be reviewed between November 1, 2007 and October 31, 2008.  Base line blood tests were drawn followed by 3-month and 6-month post-intervention blood tests for cholesterol levels and liver function tests.  Other collected data included demographics, weekly doses of statin medication, prior statin medications, patient safety and tolerance, and side effects. Outcomes: Early results indicate that cholesterol levels decreased by 20% to 40% with once-weekly dosing of rosuvastatin. Official analyses will be completed by December 31, 2008. Implications for Clinical Practice: It is predicted that high levels of cholesterol will decrease to safer levels with once-weekly rosuvastatin dosing.  Patient compliance will increase because side effects will decrease and cost savings will be realized.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Western Institute of Nursing

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleOnce-Weekly vs. Daily Statin Dosing: Evidence-Based Practice in Actionen_GB
dc.identifier.urihttp://hdl.handle.net/10755/157256-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Once-Weekly vs. Daily Statin Dosing: Evidence-Based Practice in Action</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Western Institute of Nursing</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2009</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Reavy, Kathy, PhD, RN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Boise State University, Nursing</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">1910 University Dr., Boise, ID, 83725-1840, USA</td></tr><tr class="item-phone"><td class="label">Contact Telephone:</td><td class="value">208-426-1598</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">kreavy@boisestate.edu</td></tr><tr class="item-co-authors"><td class="label">Co-Authors:</td><td class="value">Mary Hereford, Associate Professor; Sara O'Connor, Associate Professor; Mary Randall, BSN, RN</td></tr><tr><td colspan="2" class="item-abstract">Purpose:&nbsp;The purpose for this project is to validate that prescribing once-weekly rosuvastatin is a safe and effective alternative to daily statin therapy in patients who have prior intolerance and non-compliance issues. Background:&nbsp;A recurrent problem was collaboratively identified by a physician and registered nurse team in an out-patient cardiology clinic.&nbsp; Although most patients do relatively well with minimal side effects on once daily statin dosing, increasing numbers of patients were experiencing difficulty in tolerating daily statin therapy.&nbsp; The most common complaint was myalgia.&nbsp; These side effects contributed to patient non-compliance with the prescribed medication.&nbsp;&nbsp; Identification of this problem led to an evidence-based practice project to find a solution. Evidence-Based Practice Process: (1) A review of the literature found only one publication related to daily dosing of statin medications.&nbsp; A research study by Backes, Moriarty, Ruisinger, and Gibson (2007) published in The American Journal of Cardiology concluded that once weekly dosing of rosuvastatin in place of daily dosing achieved a mean reduction in LDL cholesterol of 29%, with percentages ranging from 6% to 62%. The sample size in that study, however, was only 8 patients.&nbsp; (2) Based on patient need, review of the literature, and review of pharmacologic documents, the decision was made to trial identified patients on once-weekly dosing of rosuvastatin.&nbsp; (3)&nbsp; Validation of dosing efficacy, patient safety, and patient compliance were evaluated with chart reviews.&nbsp; A minimum of 100 patient charts will be reviewed between November 1, 2007 and October 31, 2008.&nbsp; Base line blood tests were drawn followed by 3-month and 6-month post-intervention blood tests for cholesterol levels and liver function tests.&nbsp; Other collected data included demographics, weekly doses of statin medication, prior statin medications, patient safety and tolerance, and side effects. Outcomes:&nbsp;Early results indicate that cholesterol levels decreased by 20% to 40% with once-weekly dosing of rosuvastatin.&nbsp;Official analyses will be completed by December 31, 2008. Implications for Clinical Practice:&nbsp;It is predicted that high levels of cholesterol will decrease to safer levels with once-weekly rosuvastatin dosing.&nbsp; Patient compliance will increase because side effects will decrease and cost savings will be realized.</td></tr></table>en_GB
dc.date.available2011-10-26T19:42:27Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T19:42:27Z-
dc.description.sponsorshipWestern Institute of Nursingen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.